Largest Cancer Fighters Companies By Total Asset

Total Asset
Total AssetEfficiencyMarket RiskExp Return
1INO Inovio Pharmaceuticals
113.2 B
 0.02 
 4.75 
 0.09 
2BDX Becton Dickinson and
57.29 B
 0.02 
 1.35 
 0.03 
3REGN Regeneron Pharmaceuticals
37.76 B
(0.07)
 2.08 
(0.14)
4ARGX argenx NV ADR
5.99 B
(0.03)
 1.73 
(0.06)
5HALO Halozyme Therapeutics
2.06 B
 0.35 
 1.46 
 0.50 
6PTCT PTC Therapeutics
1.71 B
 0.13 
 2.58 
 0.34 
7ARRY Array Technologies
1.43 B
(0.03)
 5.32 
(0.17)
8HCM HUTCHMED DRC
1.27 B
 0.05 
 3.66 
 0.17 
9NVCR Novocure
1.24 B
(0.25)
 2.94 
(0.72)
10ZLAB Zai Lab
1.19 B
 0.17 
 3.38 
 0.58 
11BPMC Blueprint Medicines Corp
1.18 B
 0.03 
 3.64 
 0.12 
12IOVA Iovance Biotherapeutics
910.43 M
(0.24)
 4.35 
(1.03)
13CLDX Celldex Therapeutics
792.34 M
(0.11)
 3.15 
(0.33)
14MESO Mesoblast
669.15 M
(0.20)
 3.64 
(0.72)
15GERN Geron
593.78 M
(0.19)
 5.39 
(1.03)
16TGTX TG Therapeutics
577.69 M
 0.12 
 3.96 
 0.48 
17CLLS Cellectis SA
383.54 M
(0.09)
 4.93 
(0.45)
18ANGO AngioDynamics
317.67 M
 0.05 
 5.79 
 0.28 
19MGNX MacroGenics
261.65 M
(0.26)
 4.25 
(1.12)
20ADAP Adaptimmune Therapeutics Plc
245.96 M
(0.20)
 6.15 
(1.22)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value. Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.